64th ASH Annual Meeting and Exposition: 703. Cellular Immunotherapies: Basic and Translational II

Symposia: Cellular Immunotherapies: Basic and Translational Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, Biological therapies, Lymphoid Leukemias, Fundamental Science, Translational Research, Lymphomas, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, GVHD, hematopoiesis, Chronic Myeloid Malignancies, Diseases, Immune Disorders, immune mechanism, Therapies, Immunotherapy, immunology, white blood cell disorders, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, emerging technologies, Technology and Procedures, gene editing, Study Population, multi-systemic interactions, profiling, Transplantation, Animal model

393-396 (Ernest N. Morial Convention Center)

Moderators:

Mireya Paulina Velasquez, MD, and Miriam Y Kim, MD, Washington University School of Medicine

Disclosures:

No relevant conflicts of interest to declare.

4:00 PM

355

Epitope Editing in Hematopoietic Cells Enables CD45-Directed Immune Therapy

Nils Wellhausen¹, Austin K Rennels¹^*, Stefanie Lesch¹^*, Sangya Agarwal¹^*, Brooke Charria¹^*, Grace Choi¹^*, Regina M Young, PhD¹^*, Christopher Garcia²^*, Carl H June, MD^1,3,4 and Saar Gill, MD, PhD^1,5,6,7

¹Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
²School of Medicine, Stanford University School of Medicine, stanford, CA
³Parker Institute for Cancer Immunotherapy, university of Pennsylvania, Philadelphia, PA
⁴Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia
⁵Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
⁶Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁷Bone Marrow and Stem Cell Transplant Program, Hospital of the University of Pennsylvania, Philadelphia, PA

4:15 PM

356

Overcoming Heterogeneity in AML with a Novel or-Gated Hitcar-1XX Platform

Sascha Haubner, MD¹, Jorge Mansilla-Soto, PhD¹^*, Andreina Garcia Angus¹^*, Qing Chang, PhD²^*, Elisa De Stanchina, PhD²^* and Michel Sadelain, MD, PhD¹

¹Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
²Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY

4:30 PM

357

Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target

Kamal Mandal¹^*, Gianina Wicaksono¹^*, Clinton Yu²^*, Jarrett J Adams³^*, Michael R Hoopmann⁴^*, William C Temple, MD⁵, Bonell Patino Escobar¹^*, Maryna Gorelik³^*, Christian Ihling⁶^*, Matthew A Nix, PhD¹^*, Akul Naik¹^*, Emilio Ramos, MD, PhD⁷, Corynn Kasap⁸, Veronica Steri, PhD⁹^*, Juan Antonio Camara Serrano, PhD, DVM⁹^*, Fernando Salangsang⁹^*, Paul Phojanakong⁹^*, Melanie McMillan¹^*, Victor Gavallos¹^*, Andrew D Leavitt, MD¹, Andrea Sinz⁶^*, Benjamin J. Huang, MD¹⁰^*, Elliot Stieglitz, MD¹⁰^*, Catherine Smith, MD¹¹, Robert L Moritz⁴^*, Sachdeva S Sidhu³^*, Lan Huang²^* and Arun P Wiita, MD, PhD¹²

¹Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
²Department of Physiology & Biophysics, University of California Irvine, Irvine, CA
³The Donnelly Centre, University of Toronto, ON, Toronto, Canada
⁴Institute for Systems Biology, Seattle, WA
⁵Department of Pediatrics, Division of Hematology/Oncology, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, CA
⁶Department of Pharmaceutical Chemistry & Bioanalytics, Institute of Pharmacy, Martin-luther-University Halle-Wittenberg, Halle, Germany
⁷Department of Laboratory Medicine, University of California San Francisco, SF, CA
⁸Dept. of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA
⁹Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
¹⁰Dept. of Pediatrics, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA
¹¹Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, San Francisco, CA
¹²Department of Laboratory Medicine, UCSF, San Francisco, CA

4:45 PM

358

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

Sascha Haubner, MD¹, Jorge Mansilla-Soto, PhD¹^*, Sarah Nataraj, PhD¹^*, Friederike Kogel, MD¹^*, Qing Chang, PhD²^*, Elisa De Stanchina, PhD²^*, Kathryn Fraser, PhD³^*, Jae H Park, MD⁴, Xiuyan Wang, PhD⁵^*, Isabelle Riviere, PhD⁵ and Michel Sadelain, MD, PhD¹

¹Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
²Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY
³Takeda Development Center Americas, Inc., Lexington, MA
⁴Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY

5:00 PM

359

A Novel Human OX40L-CAR-Treg Specifically Targets Activated Antigen-Presenting Cells and Effectively Controls T Cell Alloreactivity and Xeno-GvHD

Xianliang Rui, PhD¹^*, Francesca Alvarez Calderon, MD, PhD^2,3,4, Ulrike Gerdemann, MD^2,3,4, Connor McGuckin²^*, Lorenzo Cagnin, PhD²^*, Bruce R. Blazar, MD⁵, Victor Tkachev, PhD^2,4 and Leslie S. Kean, MD, PhD^1,3,4

¹Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA
²Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston
³Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
⁴Department of Pediatrics, Harvard Medical School, Boston
⁵Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN

5:15 PM

360

Modulation of Host Defense in Chronic Granulomatous Disease (CGD) Via Adoptive Transfer of Neutrophil Progenitor Cells

Kristina Hinman, BS¹, Joshua T Cohen, MD²^*, Miles Mundy, BS³^* and Craig T Lefort, PhD²^*

¹Graduate Program in Pathobiology, Brown University, PROVIDENCE, RI
²Division of Surgical Research, Rhode Island Hospital, Providence, RI
³Graduate Program in Pathobiology, Brown University, Providence, RI

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.O2.6 703. Cellular Immunotherapies: Basic and Translational II